



Section 7 – Regulation FD

Item 7.01 Regulation FD Disclosure.

On September 12, 2016, Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing the initiation of stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Rexahn Pharmaceuticals, Inc. press release dated September 12, 2016, announcing the initiation of stage 2 of the Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REXAHN PHARMACEUTICALS, INC.

Date: September 12, 2016 /s/ Tae Heum Jeong

Tae Heum Jeong

Senior Vice President of Finance and Chief Financial Officer

---

Exhibit Index

Exhibit No. Description

Rexahn Pharmaceuticals, Inc. press release dated September 12, 2016, announcing the initiation of stage 2 of the 99.1 Phase Ib/IIa clinical trial with the novel oral anti-cancer agent RX-3117 in relapsed or refractory pancreatic cancer patients.

---